[The effects of blocking intrarenal renin-angiotensin system on the expression of transforming growth factor-beta1

Related Experiment Video

Updated: Oct 2, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

C Zhou1, J Li, H Wang

  • 1Department of Nephrology, First Hospital, Beijing Medical University, Beijing 100034.

Zhonghua Nei Ke Za Zhi
|January 19, 2002
PubMed
Abstract

Insights

Benazepril inhibits renal angiotensin converting enzyme (ACE) activity, reducing angiotensin II (AngII) levels. This mechanism diminishes transforming growth factor beta1 (TGF-β1) expression and extracellular matrix accumulation, slowing kidney disease progression.

Area of Science:

  • Nephrology
  • Pharmacology
  • Molecular Biology

Context:

  • Diabetic nephropathy and glomerulosclerosis are significant causes of chronic kidney disease.
  • The intrarenal renin-angiotensin system plays a crucial role in the pathogenesis of renal fibrosis.
  • Identifying therapeutic targets to inhibit renal disease progression is a key research area.

Purpose:

  • To investigate the mechanism by which benazepril ameliorates kidney disease progression.
  • To evaluate the effect of benazepril on intrarenal angiotensin converting enzyme (ACE) activity and angiotensin II (AngII) levels.
  • To assess the impact of benazepril on transforming growth factor beta1 (TGF-β1) and extracellular matrix (ECM) deposition in a rat model of glomerulosclerosis.

Summary:

  • Adriamycin-induced glomerulosclerosis in rats was treated with benazepril.
  • Benazepril significantly inhibited intrarenal ACE activity and AngII concentration.
  • This was associated with down-regulated TGF-β1 mRNA and protein expression, and reduced ECM accumulation (P < 0.01).

Impact:

  • Benazepril effectively blocks the intrarenal renin-angiotensin system.
  • This action leads to decreased TGF-β1 expression and reduced ECM accumulation.
  • These findings highlight benazepril's potential as a therapeutic agent for slowing the progression of renal diseases.

More Related Videos

Molecular Analysis of Endothelial-mesenchymal Transition Induced by Transforming Growth Factor-&#946; Signaling07:49

Molecular Analysis of Endothelial-mesenchymal Transition Induced by Transforming Growth Factor-β Signaling

Published on: August 3, 2018

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection10:15

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Action of &#946;1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
TGF - &#946; Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...